Skip to content
Screener

Monte Rosa Therapeutics, Inc. GLUE Net margin

Net margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
18.9%+8.4pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-928.4%-1,403pp
Arvinas logo
ArvinasARVN
-247.5%-260pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-285.3%-99.7pp
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-4,987.4%-8,966pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-284.2%+937pp

Other financials

Income statement

See full
Revenue$9.0M-61.3%
Operating income-$49.1M-216%
Net income-$43.4M-253%
EPS (diluted)-$0.43-187%

Balance sheet

See full
Cash & equivalents$90.1M+29.8%
Total debt$38.0M-7.6%
Total equity$487.3M+81.8%
Total assets$691.2M+92.2%

Cash flow

See full
Operating cash flow-$44.1M-27.1%
CapEx$4.7M+179%
Free cash flow-$48.8M-34.1%

Valuation

See full
Market cap$1.33B+395%
Enterprise value$1.28B+432%
P/S46.2×+44.7×

Profitability

See full
Operating margin-633%—
FCF margin-111.7%-125pp

Returns & leverage

See full
Return on equity-42.7%—
Debt / equity0.1×-0.1×
Current ratio10.6×+3.4×

Where this comes from

Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.

net income/total revenue=-560.8%

Based on trailing twelve months.

The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 7:09 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336711

FAQ

What is Monte Rosa Therapeutics, Inc.'s net margin?
Monte Rosa Therapeutics, Inc. (GLUE) reported net margin of -560.8% in Q2 2026.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.

Ask your AI about Monte Rosa Therapeutics, Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude